|
![]()
![]()
![]()
![]()
|

Aqua Pharmaceuticals, Inc. implement Quality Functions with ComplianceControl Centre
November 2011
Aqua Pharmaceuticals, Inc., USA, a specialty pharmaceutical company focusing on dermatology, in partnership with Luttrell Consulting Group, have configured and validated ComplianceControl Centre as the basis of the organizations Electronic Quality and Document Management System.
The system will be used to manage aspects of the Aqua Pharmaceuticals Quality Management System initially covering Projects, Documentation, Equipment, Training Records and Audit functions, including CAPA’s, Deviations, and Customer Complaints.
Kimberley Forbes-McKean, Ph.D., Vice President, Research & Development, Aqua Pharmaceuticals stated: “ComplianceControl Centre was selected because it is easy to use, quick to set up, and was a validated, cost effective solution for an organization of our size. We wanted a system that we could rapidly implement. Using ComplianceControl Centre will help us to ensure that we are always inspection ready, by tracking our critical Quality and Compliance activities.”
Luttrell Consulting Group carried out the configuration and validation of the hosted system. Tony Luttrell, of Luttrell Consulting Group stated: “Similar systems used by major pharmaceutical organizations were not cost effective for a specialty pharmaceutical company such as Aqua Pharmaceuticals. They wanted a system that could be validated and configured quickly, so that they could spend time using the system, not customizing and validating it. ComplianceControl Centre is a Configurable off the shelf system that really was validated and up and running in 5 days.”
David Forrest, Chief Executive of Compliance Control Ltd. stated: “We are really pleased to announce this, and the fact that an organisation such as Aqua Pharmaceuticals has chosen ComplianceControl Centre, is further recognition that our products are now starting to get good market awareness on a local and global basis and that they can provide a real return on investment for all small to medium, Life Science, Pharmaceutical and Biotech organizations”.
|
|